

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

National Parkinson Foundation

RRID:SCR_002017

Type: Tool

Proper Citation

National Parkinson Foundation (RRID:SCR_002017)

Resource Information

URL: <http://www.parkinson.org>

Proper Citation: National Parkinson Foundation (RRID:SCR_002017)

Description: The mission of the National Parkinson Foundation is to improve the quality of care for people with Parkinson's disease through research, education and outreach. NPF funds research through four main programs: the Centers of Excellence Network, which focuses on clinical studies of new therapeutic approaches; the Parkinson's Outcomes Project, a large clinical study of Parkinson's disease; the Grants/Clinical Research Fund, which provides funding to individual researchers; and fellowship awards, which are used to train neurologists in the movement disorder specialty.

Synonyms: NPF

Resource Type: topical portal, portal, funding resource, disease-related portal, data or information resource

Keywords: parkinson's disease, parkinson's disease online community, parkinson's disease organization, pd, disease related portal, funding resource

Related Condition: Parkinson's Disease

Availability: Public, Funding available to researchers

Resource Name: National Parkinson Foundation

Resource ID: SCR_002017

Alternate IDs: nif-0000-11702

License URLs: <http://www.parkinson.org/privacy>

Record Creation Time: 20220129T080211+0000

Record Last Update: 20260817T040317+0000

Ratings and Alerts

No rating or validation information has been found for National Parkinson Foundation.

No alerts have been found for National Parkinson Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Masato A, et al. (2024) Sequestosome-1 (SQSTM1/p62) as a target in dopamine catabolite-mediated cellular dyshomeostasis. *Cell death & disease*, 15(6), 424.

Caramiello AM, et al. (2024) Novel Therapeutic Horizons: SNCA Targeting in Parkinson's Disease. *Biomolecules*, 14(8).

Gangas P, et al. (2024) PROCare4Life integrated care model validation. *Open research Europe*, 4, 3.

Armitage AE, et al. (2023) Supportive care of neurodegenerative patients. *Frontiers in oncology*, 13, 1029938.

Bhidayasiri R, et al. (2022) Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice - Balancing pharmacological and non-pharmacological approaches. *Frontiers in aging neuroscience*, 14, 979826.

Ahuja M, et al. (2021) Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, 118(45).

Renko JM, et al. (2021) Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats. *Journal of Parkinson's disease*, 11(3), 1023.

Morris ME, et al. (2019) Boxing for Parkinson's Disease: Has Implementation Accelerated Beyond Current Evidence? *Frontiers in neurology*, 10, 1222.

Lytle JH, et al. (2017) A Patient's Perspective on Health Information Management. *Health literacy research and practice*, 1(1), e11.

Liu XL, et al. (2016) Effects of Health Qigong Exercises on Relieving Symptoms of Parkinson's Disease. *Evidence-based complementary and alternative medicine : eCAM*, 2016, 5935782.

Lang AE, et al. (2016) Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. *Movement disorders : official journal of the Movement Disorder Society*, 31(4), 538.

Jackman M, et al. (2016) Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy. *Tremor and other hyperkinetic movements (New York, N.Y.)*, 6, 410.

Uchihara T, et al. (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. *Acta neuropathologica*, 131(1), 49.

Nyström H, et al. (2016) Risk of Injurious Fall and Hip Fracture up to 26 y before the Diagnosis of Parkinson Disease: Nested Case-Control Studies in a Nationwide Cohort. *PLoS medicine*, 13(2), e1001954.

Gil-Prieto R, et al. (2016) Measuring the Burden of Hospitalization in Patients with Parkinson's Disease in Spain. *PloS one*, 11(3), e0151563.

Simuni T, et al. (2016) Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. *Annals of clinical and translational neurology*, 3(7), 482.

Meziane HB, et al. (2015) Movement preparation and bilateral modulation of beta activity in aging and Parkinson's disease. *PloS one*, 10(1), e0114817.

Gunduz A, et al. (2015) Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline. *The International journal of neuroscience*, 125(7), 475.

Earhart GM, et al. (2015) Comparing interventions and exploring neural mechanisms of exercise in Parkinson disease: a study protocol for a randomized controlled trial. *BMC neurology*, 15, 9.

Dorsey ER, et al. (2015) Feasibility of Virtual Research Visits in Fox Trial Finder. *Journal of Parkinson's disease*, 5(3), 505.